We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
+41.63%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.37B
AUM Growth
+$500M
Cap. Flow
+$109M
Cap. Flow %
4.61%
Top 10 Hldgs %
58.56%
Holding
56
New
7
Increased
13
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$31.4M
2
ORIC icon
Oric Pharmaceuticals
ORIC
+$23.8M
3
BBIO icon
BridgeBio Pharma
BBIO
+$23.5M
4
SLNO
Soleno Therapeutics
SLNO
+$18.6M
5
PEPG icon
PepGen
PEPG
+$17.7M

Top Sells

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$16.1M
2
DYN icon
Dyne Therapeutics
DYN
+$15.8M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$14.1M
4
APGE icon
Apogee Therapeutics
APGE
+$11.2M
5
ETNB
89bio
ETNB
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE icon
51
Apogee Therapeutics
APGE
$10.1B
– –
-400,000
Closed -$11.2M
CRNX icon
52
Crinetics Pharmaceuticals
CRNX
$8.88B
– –
-397,483
Closed -$14.1M
DYN icon
53
Dyne Therapeutics
DYN
$3.92B
– –
-1,184,840
Closed -$15.8M
MDGL icon
54
Madrigal Pharmaceuticals
MDGL
$12.8B
– –
-69,406
Closed -$16.1M
THRX
55
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
– –
-2,118,051
Closed -$8.58M
MRTX
56
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-80,000
Closed -$4.7M
1 2
3

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return

Frazier Life Sciences Management's Q1 2024 Portfolio in Review

As of Q1 2024, Frazier Life Sciences Management held 56 positions worth $2.37B, up 27% from $1.87B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Frazier Life Sciences Management deployed $109M of net new capital in Q1 2024, opening 7 new positions and adding to 13 existing holdings. Its largest new stake was CG Oncology: 770,000 shares worth $33.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was 89bio, an estimated $11.1M trimmed.

  • Frazier Life Sciences Management's largest Q1 2024 buy was CG Oncology: 770,000 shares worth $33.8M.
  • Frazier Life Sciences Management added most to Oric Pharmaceuticals in Q1 2024, an estimated $23.8M increase.
  • Frazier Life Sciences Management's biggest Q1 2024 reduction was 89bio, cutting an estimated $11.1M.
  • Frazier Life Sciences Management fully exited Madrigal Pharmaceuticals in Q1 2024, selling an estimated $16.1M.
  • Frazier Life Sciences Management's ten largest holdings make up 59% of its $2.37B portfolio in Q1 2024.
  • Frazier Life Sciences Management opened 7 new positions and closed 6 in Q1 2024.
  • Frazier Life Sciences Management's portfolio value rose 27% quarter-over-quarter to $2.37B.

Based on Frazier Life Sciences Management's 13F filing for Q1 2024, filed 15 May 2024.